Molecular Partners Ag (MOLN) EBT Margin (2020 - 2026)
Molecular Partners Ag (MOLN) posted quarterly EBT Margin of 97.78% for Q1 2026, up 613.0% year-on-year from 13.71% in Q1 2025, and down 100.07% on a QoQ basis from 143937.9% in Q4 2025.
Molecular Partners Ag (MOLN) EBT Margin (2020 - 2026) Analysis & Trends
Molecular Partners Ag (MOLN) has reported EBT Margin for 7 consecutive years, with 97.78% the latest figure, recorded in Q1 2026.
- Quarterly EBT Margin rose 613.0% year-over-year to 97.78% in Q1 2026, while the trailing twelve-month figure through Mar 2026 was 2203498.66% (up 220349756.0% YoY) and the FY2025 annual result came in at 112667814.11%, down 11266672335.0% from the prior year.
- EBT Margin retreated to 97.78% in Q1 2026 per MOLN's latest filing, from 143937.9% in the prior quarter.
- Over the last five years, EBT Margin for MOLN reached as high as 143937.9% in Q4 2025 and fell as low as 972404.9% in Q2 2024.
- A 5-year average of 49198.34% and a median of 97.78% in 2026 frame the typical range for EBT Margin.
- Annual changes were most pronounced in 2024 — EBT Margin sank 96855261 bps — and 2025, when it jumped 97228711 bps.
- Year by year, EBT Margin stood at 82.13% in 2022, then slumped by 1207 bps to 909.17% in 2023, then surged by 100 bps to 1.1% in 2024, then soared by 13113933 bps to 143937.9% in 2025, then plunged by 100 bps to 97.78% in 2026.
- According to Business Quant data, EBT Margin over the past three periods registered 97.78%, 143937.9%, and 98.26% for Q1 2026, Q4 2025, and Q3 2025 respectively.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | EBT Margin (Qtr) |
|---|---|---|---|---|---|
| 1 | Oculis Holding AG | 68,785.72 Bn | 68,785.72 Bn | - | - |
| 2 | Nanobiotix | 1,895.57 Bn | 1,895.51 Bn | - | - |
| 3 | BeOne Medicines | 471.35 Bn | 466.56 Bn | 1.35 Bn | 17.13% |
| 4 | NuCana | 279.75 Bn | 279.75 Bn | - | - |
| 5 | Vertex Pharmaceuticals | 120.24 Bn | 113.00 Bn | 2.59 Bn | 41.95% |
| 6 | Regeneron Pharmaceuticals | 67.80 Bn | 59.04 Bn | 3.31 Bn | 23.05% |
| 7 | Belite Bio | 62.51 Bn | 62.51 Bn | - | - |
| 8 | Argenx Se | 57.38 Bn | 57.38 Bn | 1.41 Bn | 34.77% |
| 9 | Revolution Medicines | 37.78 Bn | 37.78 Bn | - | - |
| 10 | Molecular Partners Ag | 147.97 Mn | 147.97 Mn | - | -97.78% |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | -97.78% |
| Dec 31, 2025 | 143,937.90% |
| Sep 30, 2025 | -98.26% |
| Jun 30, 2025 | -117.79% |
| Mar 31, 2025 | -103.90% |
| Dec 31, 2024 | 1.10% |
| Sep 30, 2024 | -2,408.81% |
| Jun 30, 2024 | -972,404.90% |
| Mar 31, 2024 | 0.00% |
| Dec 31, 2023 | -909.17% |
| Sep 30, 2023 | -450.18% |
| Jun 30, 2023 | -3,852.29% |
| Mar 31, 2023 | 0.00% |
| Dec 31, 2022 | 82.13% |
| Sep 30, 2022 | 0.00% |
| Jun 30, 2022 | -38.46% |
| Mar 31, 2022 | 88.62% |
| Dec 31, 2021 | -653.98% |
| Sep 30, 2021 | -348.40% |
| Jun 30, 2021 | 3.43% |